Australia's most trusted source of pharma news
Friday, 24 May 2019
Lost Your Access?
Seqirus boosts portfolio again
Adds schizophrenia treatment to recent expansions.
Study backs $3b+ OC pill saving
Down-scheduling could bring surge of cost reductions.
HTA patient unit is a double-up
Health Department duplicates pharma-funded service.
Safety spotlight on Lilly drug
Second time unlucky for company.
Aust pharma in Israel trial
Results expected in next 12 months for AML drug.
Sandoz antibiotic recalled
Manufacturing issue may reduce effectiveness says TGA.
Compounders take PBS millions
Pharma companies pay a heavy cost for vial sharing says STA.
Pay rises forecast for pharma
Most industry employers set to increase salaries this year.
Korean giant targets Pfizer
Multi-billion new investment in biosims aims to grab first place.
Mylan, Aspen in $188m Oz deal
ANZ script and OTC medicines sold to US generics giant.
Novartis flags CAR-T challenge
Biggest since creation of PBS Carey tells new government.
TGA fee hikes bigger than 18-19
Regulator sets out to recover growing staff, orphan costs.
Herceptin race heats up
Amgen latest to target Roche blockbuster.
Pharma in social media rut
Reticent about addressing risk and stymied by regulation.
USyd targeted on sponsorship
Caught in its own scandal on medicine research funding.
PBAC mulls asthma drug switches
Logic of gap between biologics questioned by sponsors.
Janssen seeks Invokana expansion
FDA priority for risk reduction in kidney disease and CVD.
Top of the Hill
Hunt return sparks mixed response
Not everyone might be happy to see minister back in health.
Janssen, Pfizer drugs copied
Competition added in cancer and pneumonia.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design